Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Nasus Pharma reported positive preclinical pharmacokinetic and safety results for NS003, its intranasal powder formulation of ondansetron. The animal study showed NS003 had a PK profile comparable to intravenous ondansetron, with similar Tmax and AUC, and demonstrated a favorable safety profile at four times the test dose with no adverse effects.
Key figures
- Drug Name
- NS003
- Phase Of Trial
- Preclinical
- Zofran peak sales
- $1.5 billion
- Breakthrough nausea rate
- 15-20%
- Ondansetron patients 2023
- 6 million
- Us chemo patients annually
- 1 million
- Ondansetron prescriptions 2023
- 12 million
- Radiotherapy patients annually
- 800,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.